September 24, 2012 7:27 AM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company withfully integrated commercial and drug development operations with a primaryfocus in oncology and hematology, today provided an update regardinganticipated milestones for the analysis of data and potential regulatoryfiling related to the pivotal, registrational BELIEF trial of belinostat, anovel histone deacetylase (HDAC) inhibitor. On September 21, 2012, TopotargetA/S, Spectrum's collaboration partner for the joint development of belinostat,reported preliminary clinical results for the BELIEF trial, which isevaluating the efficacy and safety of belinostat for the treatment of patientswith relapsed/refractory peripheral T-cell lymphoma (PTCL). Spectrum iscontinuing to collect and analyze the data from the trial, and database lockis expected to occur in November/December 2012, following which a definitivedetermination of the primary endpoint of overall response rate (ORR) will becalculated.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.